9 citations
,
April 2006 in “International Journal of Dermatology” DFMO may help control hair growth and treat cancer.
August 2024 in “Postgraduate Medical Journal” A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
1 citations
,
May 2025 in “Indian Dermatology Online Journal” Sorafenib can cause rare skin reactions, but treatment can continue with additional care.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
14 citations
,
July 2021 in “Bioinformatics” rPanglaoDB helps study rare cell types by merging RNA data, showing fibrocytes aid in healing.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
February 2026 in “Advanced Science” Targeting the p300/AR axis may help treat polycystic ovary syndrome.
January 2026 in “Journal of Community Medicine and Health Solutions” PP405 shows promise as a new, effective treatment for hair loss with minimal side effects.
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
April 2025 in “Pharmaceuticals” APA is a promising new compound for repairing damaged hair, outperforming Olaplex® in strength and elasticity.
14 citations
,
August 2014 in “The FASEB Journal” CAP1/Prss8 does not activate PAR2 or inhibit PN-1.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
March 2015 in “DergiPark (Istanbul University)” PUVA treatment is effective and safe for alopecia areata.
1 citations
,
October 2025 in “Micromachines” Portable point-of-care testing can improve quick and accurate genetic disorder detection.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” HDAC inhibitors, like Vorinostat and Entinostat, can help regrow hair in alopecia areata.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
September 2025 in “Cancer Innovation” Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.
29 citations
,
October 2009 in “Pharmacology Biochemistry and Behavior”
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.